Editorial: Hemopexin: newest member of the anti-inflammatory mediator club.
Fink
Mitchell P
MP
D000210:Acute-Phase Reaction / Q000276:immunology; D000818:Animals; D000893:Anti-Inflammatory Agents / Q000378:metabolism*; D016207:Cytokines / Q000037:antagonists & inhibitors / Q000276:immunology*; D015536:Down-Regulation / Q000276:immunology; D025461:Feedback, Physiological / Q000276:immunology; D006466:Hemopexin / Q000378:metabolism*; D007108:Immune Tolerance / Q000276:immunology*; D007113:Immunity, Innate / Q000276:immunology; D007249:Inflammation / Q000150:complications / Q000276:immunology* / Q000503:physiopathology*; D015850:Interleukin-6 / Q000378:metabolism; D051379:Mice; D014409:Tumor Necrosis Factor-alpha / Q000378:metabolism
D000893:Anti-Inflammatory Agents; D016207:Cytokines; D015850:Interleukin-6; D014409:Tumor Necrosis Factor-alpha; D006466:Hemopexin